You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
《美股業績》新冠疫苗商Moderna(MRNA.US)下調全年對政府銷售預期
阿思達克 08-04 10:46
新冠疫苗生產商莫德納(Moderna)(MRNA.US)公布第二季度業績。按年由盈轉虧,錄季度淨虧損13.8億美元,對上年度同期淨利潤21.97億美元。每股季度攤薄虧損3.62美元,好過市場預期虧損4.04美元。季度總收益3.44億美元,按年跌92.8%。當中新冠疫苗收入按年跌94%至2.93億美元,但仍高於市場預期的2.34億美元。季內研發成本按年升62%至11億美元。 公司預期今年對政府銷售新冠疫苗40億美元,少於原來預期的50億美元,額外10億美元對政府疫苗銷售料延後至明年。公司亦預期全年對私人市場銷售介乎20億至40億美元。 公司推算美國今年秋季對新冠疫苗需求介乎5,000萬至1億劑次,該推算乃基於美國流感市場規模。全年需求則估算為1.5億劑次。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account